BiomX Inc.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Gaithersburg, MD.

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Paul Sekhri and Alan Moses, M.D., to its Board of Directors. Mr. Sekhri brings extensive experience in the pharmaceutical and biotech sectors, including senior leadership positions at Teva, Novartis and ARIAD Pharmaceuticals. Dr. Moses brings over 25 years of clinical drug de

BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors

BiomX is focused on large market opportunities using the unique approach of manipulating the microbiome utilizing phage therapy.

BiomX: A Phage Platform Play

BiomX Inc. (PHGE) CEO Jonathan Solomon on Q2 2020 Results - Earnings Call Transcript

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical stage company developing natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results and provided a business update for the second quarter ended June 30, 2020.

BiomX Reports Second Quarter 2020 Financial Results and Provides Business Update

NESS ZIONA, Israel--(BUSINESS WIRE)--BiomX Inc. (NYSE: PHGE), a clinical-stage company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and live audio webcast on Thursday, Aug.

BiomX to Report Second Quarter 2020 Financial Results on Aug. 13, 2020

Immunovant Inc

Forget traditional IPOs! This blank check vehicle is proving to be an effective tool for biotech companies to raise capital.

Why Some Biotech Companies Are Turning to SPACs

News for BiomX Inc. Stock (PHGE)